LUND, Sweden, Aug. 20, 2020 /PRNewswire/ -- Immunovia
has today published second quarter interim report for January -
June 2020. It is available on
Immunovia's website.
"During Q2, we successfully handled COVID-19 challenges beyond
our control, strengthened
the company's economic position, began the expansion of our
sales, marketing, and customer service organizations, and are now,
despite the COVID-19 pandemic, aiming to launch the first-ever test
for early detection of pancreatic cancer during Q4 2020.
During the entire quarter, we provided continuous updates on our
focused measures to minimize the impact of the COVID-19 pandemic on
our employees, the company, and our commercialization efforts. As
we announced in May, we were forced to adjust the company's
timeline and launch date for IMMray™ PanCan-d to Q4 2020, due to
the shutdown of the state of Massachusetts, which directly impacted
important activities at our laboratory in Marlborough, MA. We were able to reopen the
Marlborough laboratory on
May 25, 2020, and we have since been
able to continue working with the greatest possible speed, energy,
and enthusiasm.
On June 4th, we successfully
implemented one of the largest capital raises ever for a non-
USA-based diagnostic company.
Immunovia announced a directed new share issue of approximately
SEK 400 million. The capital from
this new directed share issue is now being used for
commercialization activities in conjunction with the launch of
IMMray™ PanCan-d, our top priority. This capital raise allows
Immunovia to take the next step in establishing itself as a world
leader in the early detection of complex illnesses such as cancer
and autoimmune disease. It also allows the company to be more
resilient against any market volatility and ensures that we can
fully commit to our launch preparations and commercialization.
We ended the quarter with our first virtual investment day,
which included presentations by Immunovia's chairman, Carl
Borrebaeck; VD, Mats Grahn; Chief
Commercial Officer, Laura Chirica;
Senior VP Sales North America, Michael
Pettigrew; and Dr. Thomas
King, Medical Director as well as a comprehensive and
interactive Q&A session with Immunovia's stakeholders. A
highlight of the event was a virtual tour of our Marlborough laboratory. A recording of the
event can be found on our website.
On behalf of the board and the entire Immunovia team, we thank
you for your continued support of Immunovia's effort to positively
impact the lives of those at risk of pancreatic cancer. We are
launching IMMray™ PanCan-d in Q4 of this year!."
- Excerpt
from the CEO Mats Grahn's comment on
the report
Seond Quarter Interim Report for January -
June 2020 Call Details:
Immunovia invites to a teleconference (in English) for
investors, analysts and media on Thursday,
August 20, 2020 at 16:30
CET.
Mats Grahn, CEO will present
Immunovia and comment on the second quarter interim report for the
period January - June 2020 followed
by a Q&A session.
Please call in a few minutes in advance. To attend, please
dial-in at one of the numbers below and provide the conference
code Immunovia to the operator:
Conference Numbers:
Sweden: +46 (0) 8 50520424
United States: +1 212 999
6659
France: +33 (0) 1 7037 7166
Denmark: +45 3272 9273
Germany: +49 (0) 30 3001
90612
Spain: +34 91 787 0777
Netherlands: +31 (0) 20 708
5073
Norway: +47 2 156
3318
Austria: +43 (0)
12530807
Switzerland: +41 (0) 22 592
7915
UK (Standard International Access): +44 (0) 20 3003 2666
Conference Code: (to provide to the operator)
Immunovia
Immunovia
Webcast:https://channel.royalcast.com/immunovia/#!/immunovia/20200820_1
For more information, please contact:
Julie Silber, Director of
Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277
There will be an MP3-file available at Immunovia's webpage
under Investors/Financial Reports
(http://immunovia.com/investors/financial-reports/) for those who
want to listen to the telephone conference afterwards. The file
will be available within two hours after the conference has
ended.
This information is information that Immunovia AB is obliged
to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of
the contact person set out above, at 16:00
CET on August 20,
2020.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q3
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
CONTACT:
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-reports-second-quarter-interim-report-january---june-2020,c3176734
The following files are available for download:
https://mb.cision.com/Main/13121/3176734/1294756.pdf
|
Release
|